Project Grant R41AI195232
Award Date 9/23/25
Completion Date 8/31/27
Dollars Obligated $300K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Hamden, CT 06511, USA
Similar Awards
- This Project Grant award of $699,814 from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 - Allergy and Infectious Diseases Research, aims to study molecular mechanisms of Plasmodium parasite invasion in Anopheles mosquito midguts to identify novel targets for transmission-blocking malaria vaccines. The key products and services to be delivered under this award include: Functional characterization of identified mosquito and parasite proteins that mediate...
- This federal Project Grant award of $299,954 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of L2 Diagnostics LLC's novel malaria vaccine candidate called PFAG. The project aims to (i) optimize the PFAG vaccine construct and (ii) conduct efficacy testing to confirm the optimal design. PFAG is a multivalent peptide vaccine composed of synthetic peptides representing...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $813,160 to George Washington University to develop mRNA-LNP combination vaccines targeting multiple stages and species of the human malaria parasite. The grant aims to evaluate the protective efficacy of various vaccine antigens, including PFS25, PFS230, PFCSP, PVS25, and a chimeric PVCSP, both individually...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $832,071 to Seattle Children's Hospital to develop a universal transmission-blocking vaccine against malaria. The key products and services to be delivered include: Developing potent transmission-reducing monoclonal antibodies that can block vector infection across Plasmodium falciparum and Plasmodium vivax species. This...
- This $147,656 federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand the role of transmembrane proteins in the cell division process of the malaria parasite Plasmodium falciparum. The award, effective January 22, 2025 through October 31, 2027, will enable the integration of biochemical and super-resolution microscopy approaches to decipher...
- This Cooperative Agreement award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to engineer paratransgenic bacterial strains that can interfere with the ability of mosquitoes to transmit malaria parasites. The $606,815 award, granted on April 18, 2025, will fund research to develop Asaia bogorensis bacterial strains that lack antibiotic resistance genes, are resistant to horizontal...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $648,924 Project Grant to Iowa State University of Science and Technology under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The project, titled "Mosquito Extracellular Vesicles in Malaria Parasite Killing and Immune Priming," aims to obtain a mechanistic understanding of the role of mosquito extracellular vesicles in the mosquito immune system's recognition and killing of...
- This $1,174,636 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) supports the development of next-generation ELQ compounds for the treatment and prevention of malaria. The research aims to identify novel, rapidly acting anti-malarial drugs to target the blood and liver stages of the Plasmodium falciparum parasite, as well as formulations suitable for long-acting...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $281,786 to L2 Diagnostics LLC for the development of a safe and effective viral vector-based vaccine to induce both humoral and cellular immune protection against Powassan virus. The goal is to leverage the Modified Vaccinia Ankara vector platform to stimulate robust antibody and T cell responses that...
- The Project Grant titled "Impact of Antimalarials on Parasite Selection Through the Mosquito Vector" is funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $192,364 award, which runs from August 2025 to July 2030, supports research at Yale University to investigate the effect of antimalarial drugs taken by humans on the development of malaria parasites within mosquitoes. The...